All
FDA warns about contrast agent
January 1st 2007Rockville, Md. - Patients with moderate to end-stage kidney disease who undergo an MRI or MRA with a gadolinium-based contrast agent may develop nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD), a new disease that may cause death, the Food and Drug Administration warns.
Study says mycosis fungoides responds well to biological - modifier therapies
December 5th 2006National report - According to a study published in the November issue of the Journal of the American Academy of Dermatology, interleukin-12 (IL-12) produces a partial response rate of 43 percent in patients with previously treated mycosis fungoides.
Animal tests show promise for new antibody technology that fights skin cancer
December 5th 2006San Francisco ? Officials of Pain Therapeutics Inc., a biopharmaceutical company based here, is reporting that a proof-of-concept animal study of its new antibody technology for the treatment of skin cancer has produced promising results.